[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Neuroblastoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

May 2024 | 130 pages | ID: N0C9EFF4BAE8EN
IMARC Group

US$ 6,499.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The 7 major neuroblastoma markets reached a value of US$ 256.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 328.2 Million by 2034, exhibiting a growth rate (CAGR) of 2.28% during 2024-2034.

The neuroblastoma market has been comprehensively analyzed in IMARC's new report titled "Neuroblastoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuroblastoma refers to a type of cancer that develops in the immature nerve cells (neuroblasts) of the sympathetic nervous system. It usually starts in the adrenal glands, which are located above the kidneys but can also develop in other parts of the body, such as the neck, chest, abdomen, pelvis, etc. The disease generally affects infants and young children, although it can occur in adults as well. Some common symptoms are a lump in the abdomen, which may result in abdominal pain or swelling and lead to constipation or difficulty urinating. Various other indications may include bone pain, breathing problems, unexplained weight loss, fatigue, etc. In some cases, neuroblastoma may also cause fever, high blood pressure, or rapid heartbeat. The diagnosis of the ailment usually begins with a physical exam and a review of the patient's medical history. Several investigations may be used to confirm the prognosis, including imaging studies such as X-rays, ultrasounds, CT scans, MRI scans, etc., which can aid in identifying the size and location of the tumor. Additionally, numerous blood and urine tests may also be utilized to check for certain substances that are often elevated in patients with neuroblastoma. A biopsy is also performed to help confirm the diagnosis.

The increasing prevalence of genetic mutations that affect the development of nerve cells and the rising cases of chromosomal abnormalities, such as changes in the number or structure of chromosomes, are primarily driving the neuroblastoma market. In addition to this, the emerging popularity of proton therapy, since it is less damaging to the surrounding healthy tissues than traditional radiation therapy and helps treat neuroblastoma located near vital organs, is acting as another significant growth-inducing factor. Furthermore, the inflating application of gene expression profiling (GEP) to help identify the genetic signature of neuroblastoma and predict the prognosis and response to treatment is creating a positive outlook for the market. Moreover, several key players are making extensive investments in R&D activities to introduce targeted therapies that attack cancer cells while leaving healthy cells untouched, thereby improving clinical outcomes and reducing side effects. This, in turn, is also propelling the market growth. Additionally, the escalating demand for combination therapies which offer greater efficacy than single therapies alone and lower the risk of resistance developing to a single treatment is expected to drive the neuroblastoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the neuroblastoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuroblastoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuroblastoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neuroblastoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neuroblastoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neuroblastoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the neuroblastoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neuroblastoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neuroblastoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of neuroblastoma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of neuroblastoma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of neuroblastoma by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with neuroblastoma across the seven major markets?
What is the size of the neuroblastoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neuroblastoma?
What will be the growth rate of patients across the seven major markets?

Genital warts: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neuroblastoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuroblastoma market?
What are the key regulatory events related to the neuroblastoma market?
What is the structure of clinical trial landscape by status related to the neuroblastoma market?
What is the structure of clinical trial landscape by phase related to the neuroblastoma market?
What is the structure of clinical trial landscape by route of administration related to the neuroblastoma market?
1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 NEUROBLASTOMA - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 NEUROBLASTOMA - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 NEUROBLASTOMA - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
  7.2.1 Epidemiology Scenario (2018-2023)
  7.2.2 Epidemiology Forecast (2024-2034)
  7.2.3 Epidemiology by Age (?2018-2034?)
  7.2.4 Epidemiology by Gender (?2018-2034?)
  7.2.5 Diagnosed Cases (?2018-2034?)
  7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
  7.3.1 Epidemiology Scenario (2018-2023)
  7.3.2 Epidemiology Forecast (2024-2034)
  7.3.3 Epidemiology by Age (?2018-2034?)
  7.3.4 Epidemiology by Gender (?2018-2034?)
  7.3.5 Diagnosed Cases (?2018-2034?)
  7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
  7.4.1 Epidemiology Scenario (2018-2023)
  7.4.2 Epidemiology Forecast (2024-2034)
  7.4.3 Epidemiology by Age (?2018-2034?)
  7.4.4 Epidemiology by Gender (?2018-2034?)
  7.4.5 Diagnosed Cases (?2018-2034?)
  7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
  7.5.1 Epidemiology Scenario (2018-2023)
  7.5.2 Epidemiology Forecast (2024-2034)
  7.5.3 Epidemiology by Age (?2018-2034?)
  7.5.4 Epidemiology by Gender (?2018-2034?)
  7.5.5 Diagnosed Cases (?2018-2034?)
  7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
  7.6.1 Epidemiology Scenario (2018-2023)
  7.6.2 Epidemiology Forecast (2024-2034)
  7.6.3 Epidemiology by Age (?2018-2034?)
  7.6.4 Epidemiology by Gender (?2018-2034?)
  7.6.5 Diagnosed Cases (?2018-2034?)
  7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
  7.7.1 Epidemiology Scenario (2018-2023)
  7.7.2 Epidemiology Forecast (2024-2034)
  7.7.3 Epidemiology by Age (?2018-2034?)
  7.7.4 Epidemiology by Gender (?2018-2034?)
  7.7.5 Diagnosed Cases (?2018-2034?)
  7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
  7.8.1 Epidemiology Scenario (2018-2023)
  7.8.2 Epidemiology Forecast (2024-2034)
  7.8.3 Epidemiology by Age (?2018-2034?)
  7.8.4 Epidemiology by Gender (?2018-2034?)
  7.8.5 Diagnosed Cases (?2018-2034?)
  7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
  7.9.1 Epidemiology Scenario (2018-2023)
  7.9.2 Epidemiology Forecast (2024-2034)
  7.9.3 Epidemiology by Age (?2018-2034?)
  7.9.4 Epidemiology by Gender (?2018-2034?)
  7.9.5 Diagnosed Cases (?2018-2034?)
  7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 NEUROBLASTOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 NEUROBLASTOMA - UNMET NEEDS

10 NEUROBLASTOMA - KEY ENDPOINTS OF TREATMENT

11 NEUROBLASTOMA - MARKETED PRODUCTS

11.1 List of Neuroblastoma Marketed Drugs Across the Top 7 Markets
  11.1.1 Unituxin (Dinutuximab) - United Therapeutics Corporation
    11.1.1.1 Drug Overview
    11.1.1.2 Mechanism of Action
    11.1.1.3 Regulatory Status
    11.1.1.4 Clinical Trial Results
    11.1.1.5 Sales Across Major Markets
  11.1.2 Danyelza (naxitamab-gqgk) - Y mAbs Therapeutics
    11.1.2.1 Drug Overview
    11.1.2.2 Mechanism of Action
    11.1.2.3 Regulatory Status
    11.1.2.4 Clinical Trial Results
    11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 NEUROBLASTOMA - PIPELINE DRUGS

12.1 List of Neuroblastoma Pipeline Drugs Across the Top 7 Markets
  12.1.1 Ribociclib - Novartis Oncology
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
  12.1.2 67Cu-SARTATE - Clarity Pharmaceuticals
    12.1.2.1 Drug Overview
    12.1.2.2 Mechanism of Action
    12.1.2.3 Clinical Trial Results
    12.1.2.4 Safety and Efficacy
    12.1.2.5 Regulatory Status
  12.1.3 LY3295668 - Eli Lilly and Company
    12.1.3.1 Drug Overview
    12.1.3.2 Mechanism of Action
    12.1.3.3 Clinical Trial Results
    12.1.3.4 Safety and Efficacy
    12.1.3.5 Regulatory Status
  12.1.4 Racotumomab - Recombio
    12.1.4.1 Drug Overview
    12.1.4.2 Mechanism of Action
    12.1.4.3 Clinical Trial Results
    12.1.4.4 Safety and Efficacy
    12.1.4.5 Regulatory Status
  12.1.5 omburtamab - Y-mAbs Therapeutics
    12.1.5.1 Drug Overview
    12.1.5.2 Mechanism of Action
    12.1.5.3 Clinical Trial Results
    12.1.5.4 Safety and Efficacy
    12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. NEUROBLASTOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. NEUROBLASTOMA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 NEUROBLASTOMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Neuroblastoma - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Neuroblastoma - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Neuroblastoma - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Neuroblastoma - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Neuroblastoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
  15.4.1 Neuroblastoma - Market Size
    15.4.1.1 Market Size (2018-2023)
    15.4.1.2 Market Forecast (2024-2034)
  15.4.2 Neuroblastoma - Market Size by Therapies
    15.4.2.1 Market Size by Therapies (2018-2023)
    15.4.2.2 Market Forecast by Therapies (2024-2034)
  15.4.3 Neuroblastoma - Access and Reimbursement Overview
15.5 Market Scenario - France
  15.5.1 Neuroblastoma - Market Size
    15.5.1.1 Market Size (2018-2023)
    15.5.1.2 Market Forecast (2024-2034)
  15.5.2 Neuroblastoma - Market Size by Therapies
    15.5.2.1 Market Size by Therapies (2018-2023)
    15.5.2.2 Market Forecast by Therapies (2024-2034)
  15.5.3 Neuroblastoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
  15.6.1 Neuroblastoma - Market Size
    15.6.1.1 Market Size (2018-2023)
    15.6.1.2 Market Forecast (2024-2034)
  15.6.2 Neuroblastoma - Market Size by Therapies
    15.6.2.1 Market Size by Therapies (2018-2023)
    15.6.2.2 Market Forecast by Therapies (2024-2034)
  15.6.3 Neuroblastoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
  15.7.1 Neuroblastoma - Market Size
    15.7.1.1 Market Size (2018-2023)
    15.7.1.2 Market Forecast (2024-2034)
  15.7.2 Neuroblastoma - Market Size by Therapies
    15.7.2.1 Market Size by Therapies (2018-2023)
    15.7.2.2 Market Forecast by Therapies (2024-2034)
  15.7.3 Neuroblastoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
  15.8.1 Neuroblastoma - Market Size
    15.8.1.1 Market Size (2018-2023)
    15.8.1.2 Market Forecast (2024-2034)
  15.8.2 Neuroblastoma - Market Size by Therapies
    15.8.2.1 Market Size by Therapies (2018-2023)
    15.8.2.2 Market Forecast by Therapies (2024-2034)
  15.8.3 Neuroblastoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
  15.9.1 Neuroblastoma - Market Size
    15.9.1.1 Market Size (2018-2023)
    15.9.1.2 Market Forecast (2024-2034)
  15.9.2 Neuroblastoma - Market Size by Therapies
    15.9.2.1 Market Size by Therapies (2018-2023)
    15.9.2.2 Market Forecast by Therapies (2024-2034)
  15.9.3 Neuroblastoma - Access and Reimbursement Overview

16 NEUROBLASTOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 NEUROBLASTOMA MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 NEUROBLASTOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX


More Publications